CD274 and melanoma: In line with our findings, another study showed synergistic effect of I3A (20 or 40 mg/kg, intratumor injection) and anti‐PD‐L1 therapy on B16 mouse melanoma model.[19] Therefore, the therapeutic efficacy of I3A may depend on intratumoral drug concentration, and its combination with immune checkpoint inhibitors needs further study.